Does anyone else find it weird that Diamond Equities has referenced Arovella Therapeutics in a research report paid for by IMU?
Also, I couldn't see anywhere where they try to justify their 49 cent valuation.
Ann: Imugene Opens First Australian Site for azer-cel Trial, page-67
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.4¢ |
Change
-0.001(3.57%) |
Mkt cap ! $104.5M | |||
| Open | High | Low | Value | Volume |
| 1.4¢ | 1.4¢ | 1.4¢ | $23.79K | 1.707M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 64 | 18100143 | 1.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.4¢ | 3189653 | 15 |
View Market Depth
| Last trade - 10.07am 18/06/2025 (20 minute delay) ? |
| IMU (ASX) Chart |